{"id":"W4301350994","doi":"10.1136/annrheumdis-2022-eular.2076","title":"POS0296 INTEGRATED SAFETY ANALYSIS OF TOFACITINIB IN ANKYLOSING SPONDYLITIS CLINICAL TRIALS","year":2022,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada)","funders":"Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline; Amgen","keywords":"Medicine; Tofacitinib; Ankylosing spondylitis; Clinical trial; Safety profile; Internal medicine; Intensive care medicine; Rheumatoid arthritis; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0219775,0.001312805,0.002955259,0.001205532,0.0003566631,0.003210256,0.001211129,0.00165159,0.01617337],"category_scores_gemma":[0.02166853,0.0006788801,0.006728284,0.001520257,0.00075736,0.001855173,0.001040701,0.003886538,0.003190629],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001652822,"about_ca_system_score_gemma":0.003281472,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000364342,"about_ca_topic_score_gemma":0.0008147,"domain_scores_codex":[0.9816176,0.01333252,0.001123918,0.00125191,0.002024557,0.0006494654],"domain_scores_gemma":[0.9827818,0.007530109,0.004507196,0.001930909,0.002069634,0.001180226],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.7444325,0.001695338,0.009128804,0.003907314,0.0253175,0.0001954054,0.0001000817,0.006145936,0.005773704,0.002665249,0.01691592,0.1837222],"study_design_scores_gemma":[0.6168142,0.1689219,0.06150646,0.001800137,0.04494701,0.001094422,0.0001438309,0.0117227,0.006717256,0.008018048,0.0780663,0.0002477466],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7415655,0.06970666,0.02012907,0.01080995,0.00277899,0.008437035,0.06328858,0.002573955,0.0807103],"genre_scores_gemma":[0.9454045,0.006890982,0.008032684,0.004073691,0.001374076,0.003690912,0.02388082,0.000307017,0.006345256],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0219775,"threshold_uncertainty_score":0.1162295,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1708352326408879,"score_gpt":0.4573708908815567,"score_spread":0.2865356582406688,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}